Document is current
Any future updates will be listed below
-
Authors
Umbach, Alessandro
Maule, Giulia
Kheir, Eyemen
Cutarelli, Alessandro
Foglia, Marika
Guarrera, Luca
Fava, Luca L.
Conti, Luciano
Garattini, Enrico
Terao, Mineko
Cereseto, Anna https://orcid.org/0000-0003-4453-2597
-
Funding
Funding for this research was provided by:
HORIZON EUROPE Framework Programme (825825)
- License Information
-
More Information
Article History
Received: 7 April 2022
Accepted: 12 August 2022
First Online: 2 September 2022
Declarations
:
: All the experimental work using hiPSCs was conducted according to “the Guideline of iPSC use,” which is implemented in the Istituto di Ricerche Farmacologiche “Mario Negri” (IRFMN) in accordance with the “Guideline of Induced Pluripotent Stem Cells (iPSCs) Use in the Intramural Research Program” published by NIH (). All the iPSC lines used in this study were generated from peripheral blood mononuclear cells of the Cornelia de Lange Syndrome patient with the informed consent of the patient’s parents. The information related to the generation of iPSC lines is deposited in “Bio bank” file of the IRFMN. All the experimental procedures are approved by the internal “Ethical Committee” and the “Service of Prevention and Protection” of IRFMN.
: Not applicable.
: A.Ce. is a co-founder and holds stocks of Alia Therapeutics, a genome editing company.
